FDA Clearance Tracker · P990040
TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM
Last checked: Nov 20, 2026Latest source record: Sep 25, 2000 (this decision)Source: openFDAMethods & limitations
Decided
Sep 25, 2000
Approved
Time to decision
437 days
Received Jul 16, 1999. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P990040
- Device name
- TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM
- Applicant
- Cerenovus, Inc.
- Applicant location
- Miami, FL
- Received
- Jul 16, 1999
- Decided
- Sep 25, 2000
- Decision
- Approved
- Supplements
- 37 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE TRUFILL(R) N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM. THE DEVICE IS INDICATED FOR THE EMBOLIZATION OF CEREBRAL ARTERIOVENOUS MALFORMATIONS (AVMS) WHEN PRESURGICAL DEVASCULARIZATION IS DESIRED.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code KGG (tissue adhesive for use in embolization of brain arteriovenous malformations).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Cerenovus, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262419 · Decided Aug 14, 2026 · 30 days after receipt
Device type: Device, Neurovascular Embolization (HCG) · Neurology & Neurosurgery
K262398 · Decided Aug 13, 2026 · 30 days after receipt
Device type: Catheter, Thrombus Retriever (NRY) · Cardiology
- TRUFILL n-BCA Liquid Embolic System (LES), TRUFILL n-BCA Liquid Embolic System Procedural SetPMA supplement
P990040-S034 · Decided Dec 16, 2025 · 316 days after receipt · Panel Track
Device type: Neurovascular Liquid Embolic Agent (SGU) · Neurology & Neurosurgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.